Brivaracetam

Briviact, Briviact (in Italy: Nubriveo) (brivaracetam) is a small molecule pharmaceutical. Brivaracetam was first approved as Briviact on 2016-01-13. It is used to treat seizures in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A. Briviact's patents are valid until 2030-04-09 (FDA).